<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04220827</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0784</org_study_id>
    <secondary_id>NCI-2019-08320</secondary_id>
    <secondary_id>2019-0784</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT04220827</nct_id>
  </id_info>
  <brief_title>Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer</brief_title>
  <official_title>A Phase I Study of Intraperitoneal Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of paclitaxel for the treatment of&#xD;
      gastric or gastroesophageal cancer. Drugs used in chemotherapy, such as paclitaxel, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells, by stopping&#xD;
      them from dividing, or by stopping them from spreading.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To assess the maximum tolerated dose (MTD) of paclitaxel via intraperitoneal route in&#xD;
      subjects with gastric or gastroesophageal cancer and positive cytology or carcinomatosis.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Safety and tolerability of escalating doses of intraperitoneal paclitaxel in subjects with&#xD;
      gastric or gastroesophageal cancer and positive cytology or carcinomatosis.&#xD;
&#xD;
      II. To make a preliminary assessment of the anti-tumor activity of paclitaxel in subjects&#xD;
      with stage IV gastric or gastroesophageal cancer and positive cytology or carcinomatosis.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive paclitaxel intraperitoneally (IP) over 1 hour once weekly during weeks 1-3&#xD;
      and 5-7 in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 6 months for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to after 30 days after treatment completion</time_frame>
    <description>Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Safety data will be summarized using frequency tables by grade and attribution.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Clinical Stage IV Gastric Cancer AJCC v8</condition>
  <condition>Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Clinical Stage IVA Gastric Cancer AJCC v8</condition>
  <condition>Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Clinical Stage IVB Gastric Cancer AJCC v8</condition>
  <condition>Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Metastatic Gastric Adenocarcinoma</condition>
  <condition>Metastatic Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Pathologic Stage IV Gastric Cancer AJCC v8</condition>
  <condition>Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Peritoneal Carcinomatosis</condition>
  <condition>Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <condition>Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment (paclitaxel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel IP over 1 hour once weekly during weeks 1-3 and 5-7 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IP</description>
    <arm_group_label>Treatment (paclitaxel)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>Bristaxol</other_name>
    <other_name>Praxel</other_name>
    <other_name>Taxol</other_name>
    <other_name>Taxol Konzentrat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
          -  Cytologic or histologic proof of adenocarcinoma of the stomach or gastroesophageal&#xD;
             junction&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/uL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/uL&#xD;
&#xD;
          -  Platelets &gt;= 60,000/Ul&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 mg/dL&#xD;
&#xD;
          -  Distant metastatic disease of peritoneum:&#xD;
&#xD;
               -  Positive peritoneal cytology&#xD;
&#xD;
               -  Carcinomatosis on diagnostic laparoscopy or laparotomy&#xD;
&#xD;
          -  Completion of preoperative systemic chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infections such as pneumonia or wound infections that would preclude protocol therapy&#xD;
&#xD;
          -  Women with a positive urine or serum pregnancy test are excluded from this study;&#xD;
             women of childbearing potential (defined as those who are not postmenopausal defined&#xD;
             as no menses in greater than or equal to 12 months, have not had a hysterectomy or&#xD;
             bilateral salpingo-ophorectomy, do not have ovarian failure, or have not had a&#xD;
             surgical sterilization procedure) must agree to refrain from breast-feeding and&#xD;
             practice adequate contraception as specified in the informed consent. Adequate&#xD;
             contraception consists of oral contraceptive, implantable contraceptives, injectable&#xD;
             contraceptives, a double barrier method, or abstinence. Men with reproductive&#xD;
             potential must agree to an appropriate method of birth control, including abstinence&#xD;
             or double barrier method (diaphragm plus condom)&#xD;
&#xD;
          -  Subjects with unstable angina or New York Heart Association Grade II or greater&#xD;
             congestive heart failure&#xD;
&#xD;
          -  Subjects deemed unable to comply with study and/or follow-up procedures&#xD;
&#xD;
          -  Subjects with a known hypersensitivity to protocol systemic chemotherapy that was&#xD;
             life-threatening, required hospitalization or prolongation of existing&#xD;
             hospitalization, or resulted in persistent or significant disability or incapacity&#xD;
&#xD;
          -  Previous surgery that would preclude safe diagnostic laparoscopy with port placement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian D Badgwell</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian D Badgwell</last_name>
    <phone>713-792-6940</phone>
    <email>bbadgwell@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian D. Badgwell</last_name>
      <phone>713-792-6940</phone>
      <email>bbadgwell@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Brian D. Badgwell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2020</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

